Geneos Wealth Management
ARCT icon

Geneos Wealth Management’s Arcturus Therapeutics ARCT Stock Holding History

Geneos Wealth Management’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-40
Closed -$1K – 2855
2021
Q1 		$1K Buy
+40
New +$2.38K ﹤0.01% 2982

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OrbiMed
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank Julius Baer & Co
Bank Julius Baer & Co Zurich, Switzerland $38.6B AUM 35.31% 1-Year Est. Return

Geneos Wealth Management's ARCT Position: Q2 2021 in Review

Geneos Wealth Management sold out of Arcturus Therapeutics (ARCT) in Q2 2021, closing a stake of 40 shares — an estimated $1K sold.

Geneos Wealth Management first reported a position in ARCT in Q1 2021 and held it in 1 quarter. The position peaked at $1K in Q1 2021. 139 funds tracked by Wall St. Rank hold ARCT as of Q2 2021.

  • Geneos Wealth Management reported no remaining Arcturus Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Geneos Wealth Management sold 40 Arcturus Therapeutics shares in Q2 2021, an estimated $1K.
  • Geneos Wealth Management first reported a position in Arcturus Therapeutics in Q1 2021 and held it in 1 quarter.
  • Geneos Wealth Management's Arcturus Therapeutics position peaked at $1K in Q1 2021.
  • 139 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q2 2021.

Based on Geneos Wealth Management's 13F filing for Q2 2021, filed 8 Jul 2021.